Shares of Aurobindo Pharma declined by 1.03% to ₹1,641 following the company's announcement that the US Food and Drug Administration (USFDA) had closed its inspection of the Raleigh facility with 11 observations. According to the latest disclosure, the company stated that the USFDA had inspected the Raleigh plant in North Carolina, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma, from March 24 to April 10, 2025. The facility, which manufactures inhalers, dermatology and transdermal products, had received a Form 483 with 11 observations at the end of the inspection. The stock is a constituent of the Nifty Midcap 150 index and had opened higher before declining during the trading session. Aurobindo Pharma confirmed that there is no impact on the existing supplies to the US markets despite the regulatory action. As per Business Standard, the Unit has now received Establishment Inspection Report (EIR), classifying the facility as "Voluntary Action Indicated" (VAI). The USFDA has concluded that this inspection is now closed.
According to Business Standard, Aurobindo Pharma reported its fourth quarter FY26 earnings that showed solid growth across key parameters. The company's consolidated net profit increased 2% to ₹921.26 crore compared to the previous year, while net sales rose 4.4% to ₹8,751.50 crore in Q4 FY26 over Q4 FY25. The company is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. With the facility receiving a VAI classification, pending applications for multiple inhalers and other dosage forms manufactured at the facility can now progress through the USFDA's review process, as confirmed by the company. Despite the regulatory setback, Aurobindo Pharma's strong quarterly performance demonstrates the company's ability to deliver solid financial results while addressing regulatory compliance challenges.
According to Moneycontrol, Aurobindo Pharma's revenue has shown consistent growth over recent years, with annual consolidated revenue growing from ₹23,455.49 crore in 2022 to ₹33,653.08 crore in 2026, representing a 43.48% increase over five years. Net profit showed some fluctuations, decreasing from ₹2,678.36 crore in 2022 to ₹1,939.32 crore in 2023, but then recovering to ₹3,501.45 crore in 2026. The company's Earnings Per Share (EPS) increased to ₹17.86 in June 2026 from ₹15.86 in March 2026. The company's balance sheet shows healthy growth, with Reserves & Surplus increasing from ₹24,517 crore in March 2022 to ₹37,832 crore in March 2026. Total Assets also significantly rose from ₹33,921 crore to ₹58,502 crore over the same period. The company's cash flow from operating activities has consistently been positive, with ₹5,526 crore generated in March 2026.
As reported by CNBC TV18, the company's board of directors also approved the merger of Eugia Steriles, Eguia SEZ into Eugia Pharma Specialties. The merger will streamline the company's subsidiary structure and potentially enhance operational efficiency. Aurobindo Pharma recently announced the incorporation of a new wholly-owned subsidiary on August 13, 2026, which could signal future expansion plans or diversification of its business operations. With the Raleigh facility now classified as Voluntary Action Indicated (VAI), pending applications for multiple inhalers and other dosage forms filed from the site can now progress through the USFDA's review process, as confirmed by the company. According to Business Standard, as this unit is classified as VAI, pending applications for multiple inhalers and other dosage forms filed from this facility can now progress through the USFDA's review process. Despite the regulatory setback, Aurobindo Pharma's strong quarterly performance demonstrates the company's ability to deliver solid financial results while addressing regulatory compliance challenges. According to K Nithyananda Reddy, Vice-Chairman and Managing Director at Aurobindo Pharma, the company has commenced FY27 on a strong note, delivering healthy growth across its businesses through disciplined execution, operational excellence, and the continued strength of its diversified product portfolio.
